Nanoscope presents key data on retinitis pigmentosa candidate

2 May 2023

USA-based Nanoscope Therapeutics, a biotech developing gene therapies for retinal degenerative diseases, has presented results from the Phase IIb RESTORE trial of MCO-010 for the treatment of retinitis pigmentosa at the ARVO Annual Meeting.

MCO-010 is an ambient-light activatable multi-characteristic opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP), irrespective of gene mutation.

"We look forward to our upcoming conversations with the FDA on the totality of this data regarding an expeditious path to market for this exciting therapy"Composite efficacy data validate MCO-010 as a potential treatment for RP. The drug has already received both orphan drug and fast track designations from the US Food and Drug Administration (FDA).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK